Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · USD

$7.25

-0.21 (-2.8%)· Recorded snapshot

Market cap	3.6B
Net income (ttm)	-11.7M
EPS (ttm)	-$0.02
Shares out	495.9M
Volume	155,072
Beta	1.17

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -11.7M
EPS (ttm): -$0.02
Market cap: 3.6B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-128.5

P25 n/aP50 n/aP75 n/a

ROIC-76.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RGC indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001829667
Company name	Regencell Bioscience Holdings Limited
Country	Hong Kong
Country code	US
CUSIP number	G7487R100
Earnings date	2026-11-10
Earnings time	amc
Employees	10
Employees change	-2
Employees growth	-16.67%
Enterprise value	$3.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	2014
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2021-07-16
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG7487R1002
Last 10-K release date	2026-10-07
Last earnings date	2026-05-08
Last refreshed	2026-10-28
Last stock split date	2025-06-16
Last stock split type	Forward
Market cap	$3.6B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$7.25
Price currency	USD
Sector	Healthcare
SIC code	2833
Stock price date	2026-10-28
Symbol	RGC
Website	https://www.regencellbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-0.33%
FCF / EV yield	-0.21%
FCF yield	-0.21%
Industry forward P/E	13.87x
Industry P/E	173.94x
P/B ratio	277.12x
Price / tangible book value	280.46x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.2M
ROA	-71.54%
ROA (5Y)	-42.06%
ROCE	-87.44%
ROE	-128.52%
ROE (5Y)	-76.86%
ROIC	-76.93%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$80,908
EBIT	$-11.7M
EBITDA	$-11.6M
EPS	$-0.02
FCF per share	$-0.02
Financing cash flow	$16.9M
Free cash flow	$-7.7M
Free cash flow minus SBC	$-10.9M
Investing cash flow	$2.5M
Net cash flow	$11.8M
Net income	$-11.7M
Operating cash flow minus SBC	$-10.9M
Operating income	$-11.7M
Stock-based compensation	$3.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.03
Debt / equity	0.02
Long-term assets	$506,402
Long-term liabilities	$59,499
Net cash (debt)	$13.9M
Net cash / market cap	0.37%
Net cash growth	76.45%
Net debt / equity	-1.04
Piotroski F-Score	2
Property, plant and equipment	$430,732
Shareholders' equity	$13.3M
Tangible book value	$13.3M
Tangible book value per share	$0.03
Total assets	$14.7M
Total cash	$14.2M
Total debt	$295,811
Total liabilities	$1.4M
WACC	10.66%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$14.2M
Current liabilities	$1.3M
Current ratio	10.77
Net working capital	$-1.1M
Quick ratio	10.75
Working capital	$12.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.02%
Dividend yield	0%
Shareholder yield	-0.02%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$14.15
1D price change	-2.82%
1M price change	17.99%
1M total return	17.99%
1W price change	-32.59%
1W total return	-32.59%
1Y price change	-55.91%
1Y return CAGR	-55.93%
1Y total return	-55.91%
20-day SMA	$8.13
200-day SMA	$17.42
3M price change	24.87%
3M total return	24.87%
3Y price change	1,597.37%
3Y return CAGR	156.93%
3Y total return	1,597.18%
50-day SMA	$6.78
50-day SMA vs 200-day SMA	50under200
52-week high	$69.00
52-week high date	2026-01-08
52-week low	$4.51
52-week low date	2026-07-17
5Y price change	1,953.6%
5Y return CAGR	83.04%
5Y total return	1,953.75%
6M price change	-75.07%
6M total return	-75.07%
All-time high	$83.60
All-time high date	2025-06-16
All-time low	$0.08
All-time low date	2024-07-22
Average true range (ATR)	$1.10
Average volume	431.2K
Beta (1Y)	1.98
Beta (2Y)	-1.14
Beta (5Y)	1.17
Change from 52-week high	-89.49%
Change from 52-week low	60.75%
Change from all-time high	-91.29%
Change from all-time low	9,034.25%
Change from open	-2.82%
Day's gap	0%
Dollar volume	$1.1M
High price	$7.86
Low price	$7.18
Monthly RSI	45.2
Open price	$7.46
Position in 52-week range	10.29%
Premarket change	2.3%
Premarket close	$7.46
Premarket price	$7.63
Premarket volume	7.1K
Previous close	$7.46
Price vs 150-day SMA	-48.53%
Price vs 20-day SMA	-10.49%
Price vs 200-day SMA	-58.2%
Price vs 50-day SMA	7.36%
Relative volume	0.36
Return from IPO open	2,290.75%
Return from IPO price	-20.53%
RSI	46.38
Sharpe ratio	0.11
Sharpe ratio (3Y)	1.13
Sortino ratio	0.23
Sortino ratio (3Y)	3.99
Volume	155.1K
Weekly RSI	40.21
YTD price change	-65.33%
YTD total return	-65.33%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	55.6M
Float percentage	11.22%
Shares change (QoQ)	0.05%
Shares change (YoY)	0.02%
Shares held by insiders	88.55%
Shares held by institutions	0.35%
Shares outstanding	495.9M
Short % of float	1.18%
Short % of shares	0.13%
Short ratio	4 days

Deeper analysis on RGC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RGC report

Is a complete RGC research report available?

No complete published report is available for Regencell Bioscience Holdings Limited (RGC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Regencell Bioscience Holdings Limited (RGC)

Price

Financial snapshot

Fair-value bridge

Latest news · RGC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RGC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RGC

Frequently asked questions